Timothy A. Lewis

Timothy A. Lewis

Auto-generated profile, based on publicly available information

Timothy A. Lewis

Center for the Science of Therapeutics, Broad Institute , Cambridge, Massachusetts 02142, United States

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2007 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
SSSovan Sarkar
Sovan Sarkar
EPEthan O Perlstein
Ethan O Perlstein
SISara Imarisio
Sara Imarisio
SPSandra Pineau
Sandra Pineau
ACAxelle Cordenier
Axelle Cordenier
David C RubinszteinDavid C Rubinsztein
David C Rubinsztein

1 September 2016 in Cell
Verified
Journal Article
Closed access
DSDavid B. Sykes
David B. Sykes
YKYoumna S. Kfoury
Youmna S. Kfoury
FMFrançois E. Mercier
François E. Mercier
MWMathias J. Wawer
Mathias J. Wawer
JLJason M. Law
Jason M. Law
DSDavid T. Scadden
David T. Scadden

12 April 1991 in Science
Verified
Journal Article
Closed access
PDF file
JHJoel M. Hawkins
Joel M. Hawkins
AMAxel Meyer
Axel Meyer
TLTimothy A. Lewis
Timothy A. Lewis
SLStefan Loren
Stefan Loren
FHFrederick J. Hollander
Frederick J. Hollander
An x-ray crystal structure that confirms the soccer ball-shaped carbon framework of C 60 (buckminsterfullerene) is reported. An osmyl unit was added to C 60 in order to break its pseudospherical symmetry and give an ordered crystal. The crystal structure of this derivative, C 60 (OsO 4 )(4- tert -butylpyridine) 2 , reveals atomic positions within the carbon cluster.

7 September 2016 in Nature
Verified
Journal Article
Closed access
PDF file
NKNobutaka Kato
Nobutaka Kato
ECEamon Comer
Eamon Comer
TSTomoyo Sakata-Kato
Tomoyo Sakata-Kato
ASArvind Sharma
Arvind Sharma
MSManmohan Sharma
Manmohan Sharma
SSStuart L. Schreiber
Stuart L. Schreiber

1 April 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ASAnja Schuetz
Anja Schuetz
JMJinrong Min
Jinrong Min
AAAbdellah Allali-Hassani
Abdellah Allali-Hassani
MSMatthieu Schapira
Matthieu Schapira
MSMichael Shuen
Michael Shuen
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
Histone deacetylases (HDACs) are protein deacetylases that play a role in repression of gene transcription and are emerging targets in cancer therapy. Here, we characterize the structure and enzymatic activity of the catalytic domain of human HDAC7 (cdHDAC7). Although HDAC7 normally exists as part of a multiprotein complex, we show that cdHDAC7 has a low level of deacetylase activity which can be inhibited by known HDAC inhibitors. The crystal structures of human cdHDAC7 and its complexes with two hydroxamate inhibitors are the first structures of the catalytic domain of class IIa HDACs and demonstrate significant differences with previously reported class I and class IIb-like HDAC structures. We show that cdHDAC7 has an additional class IIa HDAC-specific zinc binding motif adjacent to the active site which is likely to participate in substrate recognition and protein-protein interaction and may provide a site for modulation of activity. Furthermore, a different active site topology results in modified catalytic properties and in an enlarged active site pocket. Our studies provide mechanistic insights into class IIa HDACs and facilitate the design of specific modulators.

26 January 2010 in PLOS Biology
Verified
Journal Article
Open access
PDF file
MVMarcel A. T. M. van Vugt
Marcel A. T. M. van Vugt
AGAlexandra K. Gardino
Alexandra K. Gardino
RLRune Linding
Rune Linding
GOGerard J. Ostheimer
Gerard J. Ostheimer
HRH. Christian Reinhardt
H. Christian Reinhardt
MYMichael B. Yaffe
Michael B. Yaffe
DNA damage checkpoints arrest cell cycle progression to facilitate DNA repair. The ability to survive genotoxic insults depends not only on the initiation of cell cycle checkpoints but also on checkpoint maintenance. While activation of DNA damage checkpoints has been studied extensively, molecular mechanisms involved in sustaining and ultimately inactivating cell cycle checkpoints are largely unknown. Here, we explored feedback mechanisms that control the maintenance and termination of checkpoint function by computationally identifying an evolutionary conserved mitotic phosphorylation network within the DNA damage response. We demonstrate that the non-enzymatic checkpoint adaptor protein 53BP1 is an in vivo target of the cell cycle kinases Cyclin-dependent kinase-1 and Polo-like kinase-1 (Plk1). We show that Plk1 binds 53BP1 during mitosis and that this interaction is required for proper inactivation of the DNA damage checkpoint. 53BP1 mutants that are unable to bind Plk1 fail to restart the cell cycle after ionizing radiation-mediated cell cycle arrest. Importantly, we show that Plk1 also phosphorylates the 53BP1-binding checkpoint kinase Chk2 to inactivate its FHA domain and inhibit its kinase activity in mammalian cells. Thus, a mitotic kinase-mediated negative feedback loop regulates the ATM-Chk2 branch of the DNA damage signaling network by phosphorylating conserved sites in 53BP1 and Chk2 to inactivate checkpoint signaling and control checkpoint duration. DNA is constantly damaged both by factors outside our bodies (such as ultraviolet rays from sunlight) and by factors from within (such as reactive oxygen species produced during metabolism). DNA damage can lead to malfunctioning of genes, and persistent DNA damage can result in developmental disorders or the development of cancer. To ensure proper DNA repair, cells are equipped with an evolutionarily conserved DNA damage checkpoint, which stops proliferation and activates DNA repair mechanisms. Intriguingly, this DNA damage checkpoint responds to DNA damage throughout the cell cycle, except during mitosis. In this work, we have addressed how cells dismantle their DNA damage checkpoint during mitosis to allow cell division to proceed even if there is damaged DNA present. Using the observation that kinases phosphorylate their substrates on evolutionarily conserved, kinase-specific sequence motifs, we have used a combined computational and experimental approach to predict and verify key proteins involved in mitotic checkpoint inactivation. We show that the checkpoint scaffold protein 53BP1 is phosphorylated by the mitotic kinases Cdk1 and Polo-like kinase-1 (Plk1). Furthermore, we find that Plk1 can inactivate the checkpoint kinase Chk2, which is downstream of 53BP1. Plk1 is shown to be a key mediator of mitotic checkpoint inactivation, as cells that cannot activate Plk1 fail to properly dismantle the DNA damage checkpoint during mitosis and instead show DNA damage-induced Chk2 kinase activation. Two related papers, published in PLoS Biology (Vidanes et al., doi:10.1371/journal.pbio.1000286) and PLoS Genetics (Donnianni et al., doi:10.1371/journal.pgen.1000763), similarly investigate the phenomenon of DNA damage checkpoint silencing.